Skip to main content

Table 2 Adverse events during axitinib treatment

From: Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

  Total (n = 98) HbL increase <2.3 g/dL (n = 49) HbL increase ≥2.3 g/dL (n = 49) p
All grades Grade III All grades Grade III All grades Grade III  
Fatigue 61 (62) 19 (19) 30 (61) 11 (22) 30 (61) 8 (16) 1.00
Arterial hypertension 56 (57) 32 (33) 21 (43) 16 (33) 35 (71) 16 (33) 0.0043
Diarrhoea 55 (56) 11 (11) 23 (47) 2 (4) 31 (63) 9 (18) 0.10
Dysphonia 36 (37) 1 (1) 14 (29) 1 (2) 22 (45) 0 0.09
Hand-foot syndrome 23 (23) 9 (9) 10 (20) 5 (10) 13 (26.5) 4 (8) 0.47
Anaemia 23 (23) 2 (2) 15 (31) 1 (2) 8 (16) 1 (2) 0.15*
Musculo-skeletal pain/arthralgia 19 (19) 2 (2) 7 (14) 1 (2) 12 (24) 1 (2) 0.31*
Mucositis 17 (17) 3 (3) 4 (8) 1 (2) 13 (26.5) 2 (4) 0.03*
Anorexia 17 (17) 4 (4) 6 (12) 1 (2) 11 (22) 3 (6) 0.29*
Hypothyroidism 11 (11) 0 5 (10) 0 6 (12) 0 1.00*
Nausea/vomiting 8 (8) 1 (1) 4 (8) 0 4 (8) 1 (2) 1.00*
Rash 5 (5) 1 (1) 2 (4) 0 3 (6) 1 (2) 1.00*
Proteinuria 2 (2) 2 (2) 1 (2) 1 (2) 1 (2) 1 (2) 1.00*
  1. * Fisher’s exact test; all other results obtained with chi-square test